Treatment of hirsutism with cimetidine: a prospective randomized controlled trial.
Cimetidine (Tagamet, Smith Klein, Brussels, Belgium) the histamine receptor type 2 blocker, has been suggested as a possible treatment of hirsutism. In a prospective randomized controlled trial, cimetidine 1.5 gm a day was given for 3 months to 12 moderately or severely hirsute women, while 8 other women were randomized to serve as a control group. There was no significant change in the hair growth rate in either group as measured by two assessment methods. This finding suggests that cimetidine, given in the recommended dose for a period of 3 months, does not have a beneficial effect on hirsutism.
Lissak
A
A
Department of Obstetrics and Gynecology, Carmel Hospital, Haifa, Israel.
Sorokin
Y
Y
Calderon
I
I
Dirnfeld
M
M
Lioz
H
H
Abramovici
H
H
D000293:Adolescent; D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003687:Dehydroepiandrosterone / Q000097:blood; D005260:Female; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D011446:Prospective Studies; D011897:Random Allocation
D003687:Dehydroepiandrosterone; D002927:Cimetidine